<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="and Drug Administration in 1968 as a prophylactic agent for" exact="influenza" post="and later for Parkinson’s disease. It is available as"/>
 <result pre="type of highly virulent beta-coronavirus was discovered in patients with" exact="pneumonia" post="of unknown cause. Severe acute respiratory syndrome coronavirus (SARS-CoV-2)"/>
 <result pre="samples was found to be the cause of a severe" exact="respiratory disease" post="in humans 1 . The outbreak of COVID-19 resulted"/>
 <result pre="antiviral agent that was previously used to treat patients with" exact="influenza" post="A. View this table: View inline View popup Download"/>
 <result pre="activities 15 . Amantadine can also block the assembly of" exact="influenza" post="virus during viral replication. Moreover amantadine may directly affect"/>
 <result pre="↵ Simmons, G. et al. Inhibitors of cathepsin L prevent" exact="severe acute respiratory syndrome" post="coronavirus entry. Proc. Natl. Acad. Sci. 102, 11876– 11881"/>
 <result pre="et al. Identification of a broad-spectrum antiviral small molecule against" exact="severe acute respiratory syndrome" post="coronavirus and Ebola, Hendra, and Nipah viruses by using"/>
 <result pre="10. ↵ Matsuyama, S. et al. Efficient activation of the" exact="severe acute respiratory syndrome" post="coronavirus spike protein by the transmembrane protease TMPRSS2. J."/>
</results>
